Moderate

Sickle cell disease - chronic management & hydroxycarbamide

SCD chronic · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Lifelong multidisciplinary care reducing vaso-occlusive events and organ damage through disease-modifying therapy, infection prophylaxis, vaccination, and surveillance. Hydroxycarbamide is the cornerstone disease-modifying agent.

Figures & algorithms

Blood film
Blood film

Red flags

  • New neurological deficit (stroke)
  • Rising breathlessness / hypoxia (chest syndrome, pulmonary hypertension)
  • Priapism over 4 hours
  • Rapidly enlarging spleen with falling Hb (sequestration)
  • Pregnancy (hydroxycarbamide must be stopped preconception)

Assessment

Differential diagnosis

  • Other haemoglobinopathies (HbSC, HbS/beta-thalassaemia)
  • Thalassaemia syndromes
  • Chronic haemolytic anaemia of other cause
  • Secondary pain syndrome
  • Avascular necrosis

Investigations

  • Baseline FBC, reticulocytes, HbF percentage
  • Haemoglobin electrophoresis / HPLC confirmation
  • Transcranial Doppler in children (stroke risk)
  • Renal and liver function, urinalysis for proteinuria
  • Annual retinal screening, echocardiography for pulmonary hypertension (TRV)
  • Ferritin and iron status if transfused

Management

  • Confirm genotype and establish a shared-care plan with a specialist centre
  • Ensure vaccinations (pneumococcal, meningococcal, Hib, annual influenza, COVID) and lifelong penicillin prophylaxis
  • Offer hydroxycarbamide to reduce painful crises, acute chest syndrome and transfusion need
  • Start hydroxycarbamide and titrate upward every 8-12 weeks to maximum tolerated dose, monitoring FBC for cytopenias
  • Give daily folic acid and address hydration, analgesia plan and crisis self-management
  • Use chronic transfusion or exchange for primary/secondary stroke prevention and high TCD velocities
  • Monitor for and manage iron overload with chelation if regularly transfused
  • Screen annually for retinopathy, nephropathy, pulmonary hypertension and avascular necrosis
  • Discuss newer agents (voxelotor, crizanlizumab, L-glutamine) and curative options (stem cell transplant, gene therapy) where appropriate
  • Provide contraception/pregnancy counselling and psychological support

Drugs & doses

Hydroxycarbamide 15-20 mg/kg PO once daily, titrate by 5 mg/kg every 8-12 weeks to max ~35 mg/kg/day
Folic acid 5 mg PO once daily
Phenoxymethylpenicillin 250 mg PO twice daily (lifelong prophylaxis)
Deferasirox 14-28 mg/kg PO once daily if transfusional iron overload

Disposition

Specialist haemoglobinopathy centre shared care; regular outpatient surveillance; admit for acute complications.

Complications & pitfalls

  • Cerebrovascular events
  • Chronic kidney disease and proteinuria
  • Pulmonary hypertension
  • Avascular necrosis of femoral head
  • Retinopathy, leg ulcers, iron overload
  • Hydroxycarbamide-induced cytopenias

Exam pearls

  • Hydroxycarbamide works largely by raising fetal haemoglobin - benefits accrue over months
  • Stop hydroxycarbamide before conception (teratogenic)
  • Annual transcranial Doppler guides stroke prophylaxis in children
  • Penicillin prophylaxis and vaccination are lifesaving against encapsulated organisms
  • Gene therapy and transplant now offer potential cure in selected patients

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.